Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) Director Christy Jones sold 1,406 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $15.00, for a total transaction of $21,090.00. Following the completion of the transaction, the director directly owned 25,994 shares in the company, valued at $389,910. This trade represents a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christy Jones also recently made the following trade(s):
- On Thursday, June 4th, Christy Jones sold 2,811 shares of Beta Bionics stock. The stock was sold at an average price of $14.00, for a total transaction of $39,354.00.
- On Thursday, May 21st, Christy Jones sold 1,998 shares of Beta Bionics stock. The stock was sold at an average price of $9.95, for a total value of $19,880.10.
Beta Bionics Stock Up 8.0%
Shares of BBNX stock opened at $15.91 on Friday. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71. The business’s 50 day moving average is $12.05 and its two-hundred day moving average is $15.57. The company has a market cap of $708.95 million, a PE ratio of -10.54 and a beta of 3.40.
Institutional Investors Weigh In On Beta Bionics
Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Beta Bionics by 213.5% in the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock valued at $44,036,000 after buying an additional 1,509,217 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Beta Bionics in the 4th quarter valued at about $40,437,000. Eversept Partners LP increased its position in Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after acquiring an additional 736,576 shares in the last quarter. 12 West Capital Management LP bought a new position in shares of Beta Bionics in the fourth quarter worth about $17,520,000. Finally, Bruce & Co. Inc. bought a new position in shares of Beta Bionics in the first quarter worth about $5,518,000.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on BBNX shares. Leerink Partners decreased their price target on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. Bank of America dropped their price objective on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research note on Monday, May 18th. Weiss Ratings lowered shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. Stifel Nicolaus lowered their target price on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Finally, Wall Street Zen lowered shares of Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.70.
View Our Latest Stock Analysis on BBNX
Beta Bionics Company Profile
Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.
At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.
Read More
- Five stocks we like better than Beta Bionics
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
